Store

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics in Moscow. It consists of the ACTH(4-10) fragment with a Pro-Gly-Pro tripeptide tail attached at the C-terminus. That tail is the key design element: it confers marked resistance to enzymatic degradation while stripping the parent fragment of its hormonal activity, so Semax does not stimulate cortisol release the way ACTH does.

Published research associates Semax with increased expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus, and with modulation of monoaminergic signalling. A recurring observation in the literature is that its measured effects persist well beyond the point at which the peptide itself has cleared from plasma, consistent with a mechanism acting through gene expression rather than direct receptor occupancy.

Semax is a registered medicine in Russia. It holds no marketing authorisation in India, the United States or the European Union. Supplied in a 3 mL pre-filled pen at 5 mg/mL (15 mg total peptide).